Maryland company Emergent BioSolutions has received a contract to supply anthrax vaccine solutions for the US military.
Valued up to $235.8 million, the firm will deliver its proprietary BioThrax vaccine adsorbed products to the US Department of Defense that will be used as pre-exposure prophylaxis for the disease.
Work for the contract will take place over five years, with an additional option to extend the project until 2033.
“As a part of our mission to protect and enhance lives, Emergent is proud to continue supporting and preparing our nation’s service members who have a high risk of exposure to anthrax bacteria by supplying BioThrax vaccine,” Emergent BioSolutions SVP Paul Williams stated.
“This new contract award is a testament to the importance of Emergent’s medical countermeasures portfolio, and we look forward to delivering on our commitments to the US DoD.”
Anthrax is transmitted from animals to humans and can cause damage to organ systems, inflammation of the brain and spinal cord, and death.
The bacteria can affect Individuals, livestock, and wild game via ingestion, skin contact, and inhalation.